Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
Go back to Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 528.46 +32.39 (6.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $496.07 | 52 Week High | $134.71 | |||
| Open | $539.50 | 52 Week Low | $73.31 | |||
| Day High | $546.17 | P/E | N/A | |||
| Day Low | $527.59 | EPS | $-1.98 | |||
| Volume | 647,129 | |||||
